Abbott launches XIENCE PRIME for coronary artery disease

Abbott has announced the availability of XIENCE PRIME – an everolimus eluting coronary stent system for the treatment of coronary artery disease.

The drug, which received the CE mark in June, offers a delivery system designed for greater flexibility and enhanced deliverability, as well as a novel stent design.

It is now available in European countries and international markets, such as Latin America and Asia Pacific.

Antonio Bartorelli, director of the interventional cardiology department of the Centro Cardiologico Monzino, University of Milan, stated: “Abbott’s XIENCE PRIME is an improvement in design, deliverability and conformability, all of which can be distinctly observed during coronary stent procedures, in both everyday and complex lesions.”

He added that it allows for easy usage, even in “complex cases”.

In other Abbott news, the firm announced last week that it is teaming up with Pfizer to develop a new molecular diagnostic test intended to screen non-small cell lung cancer tumors for the presence of gene rearrangements.